Immunotherapy Plus Chemotherapy Before Surgery Improves Outcomes for Patients with Lung Cancer
Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death
Source: indiaeducationdiary.in
